Institution
Hebei Medical University
Education•Shijiazhuang, China•
About: Hebei Medical University is a education organization based out in Shijiazhuang, China. It is known for research contribution in the topics: Cancer & Apoptosis. The organization has 18398 authors who have published 11824 publications receiving 146466 citations.
Topics: Cancer, Apoptosis, Cell growth, Medicine, Cell cycle
Papers published on a yearly basis
Papers
More filters
••
Daniel J. Klionsky1, Fábio Camargo Abdalla2, Hagai Abeliovich3, Robert T. Abraham4 +1284 more•Institutions (463)
TL;DR: These guidelines are presented for the selection and interpretation of methods for use by investigators who aim to examine macroautophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Abstract: In 2008 we published the first set of guidelines for standardizing research in autophagy. Since then, research on this topic has continued to accelerate, and many new scientists have entered the field. Our knowledge base and relevant new technologies have also been expanding. Accordingly, it is important to update these guidelines for monitoring autophagy in different organisms. Various reviews have described the range of assays that have been used for this purpose. Nevertheless, there continues to be confusion regarding acceptable methods to measure autophagy, especially in multicellular eukaryotes. A key point that needs to be emphasized is that there is a difference between measurements that monitor the numbers or volume of autophagic elements (e.g., autophagosomes or autolysosomes) at any stage of the autophagic process vs. those that measure flux through the autophagy pathway (i.e., the complete process); thus, a block in macroautophagy that results in autophagosome accumulation needs to be differentiated from stimuli that result in increased autophagic activity, defined as increased autophagy induction coupled with increased delivery to, and degradation within, lysosomes (in most higher eukaryotes and some protists such as Dictyostelium) or the vacuole (in plants and fungi). In other words, it is especially important that investigators new to the field understand that the appearance of more autophagosomes does not necessarily equate with more autophagy. In fact, in many cases, autophagosomes accumulate because of a block in trafficking to lysosomes without a concomitant change in autophagosome biogenesis, whereas an increase in autolysosomes may reflect a reduction in degradative activity. Here, we present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macroautophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes. These guidelines are not meant to be a formulaic set of rules, because the appropriate assays depend in part on the question being asked and the system being used. In addition, we emphasize that no individual assay is guaranteed to be the most appropriate one in every situation, and we strongly recommend the use of multiple assays to monitor autophagy. In these guidelines, we consider these various methods of assessing autophagy and what information can, or cannot, be obtained from them. Finally, by discussing the merits and limits of particular autophagy assays, we hope to encourage technical innovation in the field.
4,316 citations
••
TL;DR: This work aims to investigate the clinical characteristic and allergy status of patients infected with SARS‐CoV‐2 and its spread around the world.
Abstract: Background Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been widely spread. We aim to investigate the clinical characteristic and allergy status of patients infected with SARS-CoV-2. Methods Electronic medical records including demographics, clinical manifestation, comorbidities, laboratory data, and radiological materials of 140 hospitalized COVID-19 patients, with confirmed result of SARS-CoV-2 viral infection, were extracted and analyzed. Results An approximately 1:1 ratio of male (50.7%) and female COVID-19 patients was found, with an overall median age of 57.0 years. All patients were community-acquired cases. Fever (91.7%), cough (75.0%), fatigue (75.0%), and gastrointestinal symptoms (39.6%) were the most common clinical manifestations, whereas hypertension (30.0%) and diabetes mellitus (12.1%) were the most common comorbidities. Drug hypersensitivity (11.4%) and urticaria (1.4%) were self-reported by several patients. Asthma or other allergic diseases were not reported by any of the patients. Chronic obstructive pulmonary disease (COPD, 1.4%) patients and current smokers (1.4%) were rare. Bilateral ground-glass or patchy opacity (89.6%) was the most common sign of radiological finding. Lymphopenia (75.4%) and eosinopenia (52.9%) were observed in most patients. Blood eosinophil counts correlate positively with lymphocyte counts in severe (r = .486, P Conclusion Detailed clinical investigation of 140 hospitalized COVID-19 cases suggests eosinopenia together with lymphopenia may be a potential indicator for diagnosis. Allergic diseases, asthma, and COPD are not risk factors for SARS-CoV-2 infection. Older age, high number of comorbidities, and more prominent laboratory abnormalities were associated with severe patients.
2,999 citations
••
University of Oxford1, Virginia Commonwealth University2, Capital Medical University3, Nanjing Medical University4, Hebei Medical University5, Harbin Medical University6, Shantou University7, Sichuan University8, Sun Yat-sen University9, Chongqing University10, Jinan University11, Xi'an Jiaotong University12, Shanxi Medical University13, Zhengzhou University14, Lanzhou University15, Central South University16, Jiangsu University17, Wuhan University18, Zhejiang Chinese Medical University19, China Medical University (PRC)20, Kanazawa Medical University21, Tianjin First Center Hospital22, Tongji University23, Fourth Military Medical University24, Max Planck Society25, Shanghai Jiao Tong University26, Fudan University27, Peking Union Medical College28, Macau University of Science and Technology29, University of Copenhagen30, King Abdulaziz University31, East China Normal University32
TL;DR: Using low-coverage whole-genome sequencing of 5,303 Chinese women with recurrent MDD selected to reduce phenotypic heterogeneity, and 5,337 controls screened to exclude MDD, two loci contributing to risk of MDD on chromosome 10 are identified: one near the SIRT1 gene and the other in an intron of the LHPP gene.
Abstract: Genomic analysis of 5,303 Chinese women with recurrent major depressive disorder (MDD) enables the identification and replication of two genome-wide significant loci contributing to risk of MDD on chromosome 10: one near the SIRT1 gene; the other in an intron of the LHPP gene.
745 citations
••
Peking Union Medical College1, Duke University2, Peking University3, Centers for Disease Control and Prevention4, Hebei Medical University5, Fujian Medical University6, Cancer Council Queensland7, International Agency for Research on Cancer8, American Cancer Society9, Cancer Council New South Wales10
TL;DR: There was a marked overall increase in cancer survival from 2003 to 2015 in the population covered by these cancer registries in China, possibly reflecting advances in the quality of cancer care in these areas.
738 citations
••
Fudan University1, Nanchang University2, Nanjing Medical University3, Harbin Medical University4, Hebei Medical University5, Peking Union Medical College6, China Medical University (PRC)7, Sun Yat-sen University8, Qingdao University9, Fujian Medical University10, Sichuan University11, Bengbu Medical College12, Fourth Military Medical University13, Tianjin Medical University Cancer Institute and Hospital14, Shanghai Jiao Tong University15, Third Military Medical University16, Zhejiang University17, Shantou University18
TL;DR: These data show that apatinib treatment significantly improved OS and PFS with an acceptable safety profile in patients with advanced gastric cancer refractory to two or more lines of prior chemotherapy.
Abstract: PurposeThere is currently no standard treatment strategy for patients with advanced metastatic gastric cancer experiencing progression after two or more lines of chemotherapy. We assessed the efficacy and safety of apatinib, a novel vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor, in patients with advanced gastric or gastroesophageal junction adenocarcinoma for whom at least two lines of prior chemotherapy had failed.Patients and MethodsThis was a randomized, double-blind, placebo-controlled phase III trial. Patients from 32 centers in China with advanced gastric or gastroesophageal junction adenocarcinoma, for whom two or more prior lines of chemotherapy had failed, were enrolled. Patients were randomly assigned to oral apatinib 850 mg or placebo once daily. The primary end points were overall (OS) and progression-free survival (PFS).ResultsBetween January 2011 and November 2012, 267 patients were enrolled. Median OS was significantly improved in the apatinib group compared with t...
711 citations
Authors
Showing all 18434 results
Name | H-index | Papers | Citations |
---|---|---|---|
Yi Yang | 143 | 2456 | 92268 |
Olle Melander | 109 | 783 | 75911 |
Wei Liu | 102 | 2927 | 65228 |
Stephen C. Pflugfelder | 95 | 437 | 32767 |
Xiang Gao | 92 | 1359 | 42047 |
Qian Liu | 90 | 610 | 33341 |
Jan Nilsson | 79 | 436 | 27704 |
Fan Zhang | 77 | 517 | 30865 |
Wei Zhao | 77 | 479 | 30589 |
Gunnar Engström | 74 | 484 | 20438 |
Jian Cao | 58 | 486 | 11074 |
Zhongchao Han | 58 | 312 | 11857 |
Yi Liu | 58 | 537 | 14291 |
Yingze Zhang | 52 | 655 | 12550 |
Nipavan Chiamvimonvat | 51 | 171 | 7423 |